[{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"SARM1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nura Bio","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"5","companyTruncated":"Nura Bio \/ The Column Group"},{"orgOrder":0,"company":"Nura Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"SARM1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nura Bio \/ Not Applicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NB-4746","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Nura Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nura Bio \/ Not Applicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"Caffeine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nura Bio","amount2":0.14000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"14","companyTruncated":"Nura Bio \/ The Column Group"}]

Find Clinical Drug Pipeline Developments & Deals by Nura Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The financing will support the clinical development of NB-4746, a SARM1 inhibitor currently being evaluated in early-stage trials for the treatment of amyotrophic lateral sclerosis.

                          Brand Name : NB-4746

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 17, 2024

                          Lead Product(s) : NB-4746,Caffeine,Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : The Column Group

                          Deal Size : $140.0 million

                          Deal Type : Series A Financing

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : NB-4746 is believed to be a first-in-class, oral, brain-penetrant, neuroprotective SARM1 inhibitor with broad therapeutic potential across diseases of the central, peripheral, and ocular nervous systems.

                          Brand Name : NB-4746

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 25, 2023

                          Lead Product(s) : NB-4746

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Publication of research elucidating molecular details of conserved, NAD-dependent inhibitory mechanism that results in highly potent small molecule inhibitors of NAD hydrolases like SARM1 and CD38.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 13, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Nura Bio seeks to alter the course of neurological disease by targeting the fundamental pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 29, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : The Column Group

                          Deal Size : $73.0 million

                          Deal Type : Series A Financing

                          blank